Attenuation of Pseudomonas aeruginosa infection by INP0341, a salicylidene acylhydrazide, in a murine model of keratitis

References

• Stapleton F, Carnt N. Contact lens-related microbial keratitis: how have epidemiology and genetics helped us with pathogenesis and prophylaxis. Eye (Lond). 2012;26:185–193.
   PubMed Web of Science ®Google Scholar
• Sun Y, Karmakar M, Roy S, et al. TLR4 and TLR5 on corneal macrophages regulate Pseudomonas aeruginosa keratitis by signaling through MyD88-dependent and -independent pathways. J Immunol. 2010;185:4272–4283.
   PubMed Web of Science ®Google Scholar
• Evans DJ, Fleiszig SM. Why does the healthy cornea resist Pseudomonas aeruginosa infection? Am J Ophthalmol. 2013;155(961–70):e2.
   Google Scholar
• Roy S, Sun Y, Pearlman E. Interferon-gamma-induced MD-2 protein expression and lipopolysaccharide (LPS) responsiveness in corneal epithelial cells is mediated by Janus tyrosine kinase-2 activation and direct binding of STAT1 protein to the MD-2 promoter. J Biol Chem. 2011;286:23753–23762.
   PubMed Web of Science ®Google Scholar
• Karthikeyan RS, Priya JL, Leal SM Jr., et al. Host response and bacterial virulence factor expression in Pseudomonas aeruginosa and streptococcus pneumoniae corneal ulcers. PLoS One. 2013;8:e64867.
   PubMed Web of Science ®Google Scholar
• Sharma P, Guha S, Garg P, et al. Differential expression of antimicrobial peptides in corneal infection and regulation of antimicrobial peptides and reactive oxygen species by type III secretion system of Pseudomonas aeruginosa. Pathog Dis. 2018;76. DOI:https://doi.org/10.1093/femspd/fty001
   Google Scholar
• Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nature Rev Microbiol. 2009;7:654–665.
   PubMed Web of Science ®Google Scholar
• Sundin C, Hallberg B, Forsberg A. ADP-ribosylation by exoenzyme T of Pseudomonas aeruginosa induces an irreversible effect on the host cell cytoskeleton in vivo. FEMS Microbiol Lett. 2004;234:87–91.
   PubMed Web of Science ®Google Scholar
• Vareechon C, Zmina SE, Karmakar M, et al. Pseudomonas aeruginosa effector ExoS inhibits ROS production in human neutrophils. Cell Host Microbe. 2017;21:611–8 e5.
   PubMed Web of Science ®Google Scholar
• Lambert PA. Mechanisms of antibiotic resistance in Pseudomonas aeruginosa. J R Soc Med. 2002;95(Suppl 41):22–26.
   PubMed Web of Science ®Google Scholar
• Rocchetta HL, Burrows LL, Lam JS. Genetics of O-antigen biosynthesis in Pseudomonas aeruginosa. Microbiol Mol Biol Rev. 1999;63:523–553.
   PubMed Web of Science ®Google Scholar
• Hoiby N, Bjarnsholt T, Moser C, et al. ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. Clin Microbiol Infect. 2015;21(Suppl 1):S1–25. .
   PubMedGoogle Scholar
• Negrea A, Bjur E, Ygberg SE, et al. Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium. Antimicrob Agents Chemother. 2007;51:2867–2876.
   PubMed Web of Science ®Google Scholar
• Veenendaal AK, Sundin C, Blocker AJ. Small-molecule type III secretion system inhibitors block assembly of the Shigella type III secreton. J Bacteriol. 2009;191:563–570.
   PubMed Web of Science ®Google Scholar
• Kauppi AM, Nordfelth R, Uvell H, et al. Targeting bacterial virulence: inhibitors of type III secretion in Yersinia. Chem Biol. 2003;10:241–249.
   PubMed Web of Science ®Google Scholar
• Uusitalo P, Hagglund U, Rhoos E, et al. The salicylidene acylhydrazide INP0341 attenuates Pseudomonas aeruginosa virulence in vitro and in vivo. J Antibiot (Tokyo). 2017;70:937–943.
   PubMed Web of Science ®Google Scholar
• Chu H, Slepenkin A, Elofsson M, et al. Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseriagonorrhoeae. Int J Antimicrob Agents. 2010;36:145–150.
   PubMed Web of Science ®Google Scholar
• Pedersen C, Slepenkin A, Andersson SB, et al. Formulation of the microbicide INP0341 for in vivo protection against a vaginal challenge by Chlamydia trachomatis. PLoS One. 2014;9:e110918.
   PubMed Web of Science ®Google Scholar
• Slepenkin A, Enquist PA, Hagglund U, et al. Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron. Infect Immun. 2007;75:3478–3489.
   PubMed Web of Science ®Google Scholar
• Bleves S, Soscia C, Nogueira-Orlandi P, et al. Quorum sensing negatively controls type III secretion regulon expression in Pseudomonas aeruginosa PAO1. J Bacteriol. 2005;187:3898–3902.
   PubMed Web of Science ®Google Scholar
• Cisz M, Lee PC, Rietsch A. ExoS controls the cell contact-mediated switch to effector secretion in Pseudomonas aeruginosa. J Bacteriol. 2008;190:2726–2738.
   PubMedGoogle Scholar
• Sharma P, Sharma N, Mishra P, et al. Differential expression of antimicrobial peptides in streptococcus pneumoniae keratitis and STAT3-dependent expression of LL-37 by streptococcus pneumoniae in human corneal epithelial cells. Pathogens. 2019;8:31–48.
   Web of Science ®Google Scholar
• Roy S, Bonfield T, Tartakoff AM. Non-apoptotic toxicity of Pseudomonas aeruginosa toward murine cells. PLoS One. 2013;8:e54245.
   PubMedGoogle Scholar
• Araki-Sasaki K, Ohashi Y, Sasabe T, et al. An SV40-immortalized human corneal epithelial cell line and its characterization. Invest Ophthalmol Vis Sci. 1995;36:614–621.
   PubMed Web of Science ®Google Scholar
• Ponsoda X, Jover R, Castell JV, et al. Measurement of intracellular LDH activity in 96-well cultures: A rapid and automated assay for cytotoxicity studies. J Tissue Culture Methods. 1991;13:21–24.
   Google Scholar
• Pan Z, Chen Y, Zhang W, et al. Rat corneal allograft survival prolonged by the superantigen staphylococcal enterotoxin B. Invest Ophthalmol Vis Sci. 2003;44:3346–3351.
   PubMed Web of Science ®Google Scholar
• Allen M, Millett P, Dawes E, et al. Lactate dehydrogenase activity as a rapid and sensitive test for the quantification of cell numbers in vitro. Clin Mater. 1994;16:189–194.
   PubMedGoogle Scholar
• O’Grady EP, Mulcahy H, O’Callaghan J, et al. Pseudomonas aeruginosa infection of airway epithelial cells modulates expression of Kruppel-like factors 2 and 6 via RsmA-mediated regulation of type III exoenzymes S and Y. Infect Immun. 2006;74:5893–5902.
   PubMed Web of Science ®Google Scholar
• Cowell BA, Evans DJ, Fleiszig SM. Actin cytoskeleton disruption by ExoY and its effects on Pseudomonas aeruginosa invasion. FEMS Microbiol Lett. 2005;250:71–76.
   PubMed Web of Science ®Google Scholar
• Sun Y, Karmakar M, Taylor PR, et al. ExoS and ExoT ADP ribosyltransferase activities mediate Pseudomonas aeruginosa keratitis by promoting neutrophil apoptosis and bacterial survival. J Immunol. 2012;188:1884–1895.
   PubMed Web of Science ®Google Scholar
• Breidenstein EB, de la Fuente-nunez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 2011;19:419–426.
   PubMed Web of Science ®Google Scholar
• Gauthier A, Robertson ML, Lowden M, et al. Transcriptional inhibitor of virulence factors in enteropathogenic Escherichia coli. Antimicrob Agents Chemother. 2005;49:4101–4109.
   PubMed Web of Science ®Google Scholar
• Enquist PA, Gylfe A, Hagglund U, et al. Derivatives of 8-hydroxyquinoline–antibacterial agents that target intra- and extracellular Gram-negative pathogens. Bioorg Med Chem Lett. 2012;22:3550–3553.
   PubMed Web of Science ®Google Scholar
• Anantharajah A, Faure E, Buyck JM, et al. Inhibition of the injectisome and flagellar type III secretion systems by INP1855 Impairs Pseudomonas aeruginosa pathogenicity and inflammasome activation. J Infect Dis. 2016;214:1105–1116.
   PubMed Web of Science ®Google Scholar
• Bowlin NO, Williams JD, Knoten CA, et al. Mutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system. Antimicrob Agents Chemother. 2014;58:2211–2220.
   PubMed Web of Science ®Google Scholar
• Berube BJ, Murphy KR, Torhan MC, et al. Impact of type III secretion effectors and of phenoxyacetamide inhibitors of type III secretion on abscess formation in a mouse model of Pseudomonas aeruginosa infection. Antimicrob Agents Chemother. 2017;61. DOI:https://doi.org/10.1128/AAC.01202-17.
   Google Scholar
• Kimura K, Iwatsuki M, Nagai T, et al. A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium. J Antibiot (Tokyo). 2011;64:197–203.
   PubMed Web of Science ®Google Scholar
• Bailey L, Gylfe A, Sundin C, et al. Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle. FEBS Lett. 2007;581:587–595.
   PubMed Web of Science ®Google Scholar
• Nordfelth R, Kauppi AM, Norberg HA, et al. Small-molecule inhibitors specifically targeting type III secretion. Infect Immun. 2005;73:3104–3114.
   PubMed Web of Science ®Google Scholar
• Slepenkin A, Chu H, Elofsson M, et al. Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide. J Infect Dis. 2011;204:1313–1320.
   PubMed Web of Science ®Google Scholar
• Forthal DN, Phan TB, Slepenkin AV, et al. In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds. Int J Antimicrob Agents. 2012;40:354–360.
   PubMed Web of Science ®Google Scholar